UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20569
FORM 10-Q
/X/ Quarterly Report Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Or
/ / Transition Report Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
For the Quarterly Period Ended Commission file number
September 30, 2000 0-23150
------------------ -------
IBIS TECHNOLOGY CORPORATION
- ----------------------------------------------------------------------------
(Exact name of registrant as specified in its charter)
MASSACHUSETTS 04-2987600
- ----------------------------- --------------------
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
32 CHERRY HILL DRIVE, DANVERS, MA 01923
- -----------------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
(978) 777-4247
- -----------------------------------------------------------------------------
(Registrant's telephone number, including area code)
Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days.
Yes X No ___
8,319,328 shares of Common Stock, par value $.008, were outstanding on
November 6, 2000.
Total Number of Pages 39
Exhibit Index at Page 19
IBIS TECHNOLOGY CORPORATION
INDEX
PAGE
PART 1 - FINANCIAL INFORMATION NUMBER
- ------------------------------- ------
Item 1 - Financial Statements:
Balance Sheets
December 31, 1999 and September 30, 2000....................... 3
Statements of Operations
Three Months Ended September 30, 1999 and 2000 4
and Nine Months Ended September 30, 1999 and 2000. ............
Statements of Cash Flows
Nine Months Ended September 30, 1999 and 2000................... 5
Notes to Financial Statements...................................... 6
Item 2 - Management's Discussion and Analysis of Financial
Condition and Results of Operations............................ 10
Item 3 - Quantitative and Qualitative Disclosure About Market Risk... 16
PART II - OTHER INFORMATION
- ---------------------------
Item 1 - Legal Proceedings............................................. 17
Item 2 - Changes in Securities......................................... 17
Item 3 - Defaults upon Senior Securities............................... 17
Item 4 - Submission of Matters to a Vote of Security Holders........... 17
Item 5 - Other Information............................................. 17
Item 6 - Exhibits and Reports on Form 8-K.............................. 17
Signatures............................................................. 18
Exhibit
Index.................................................................. 19
2
IBIS TECHNOLOGY CORPORATION
BALANCE SHEETS
DECEMBER 31, SEPTEMBER 30,
1999 2000
------- --------
(UNAUDITED)
ASSETS
- ------
CURRENT ASSETS:
Cash and cash equivalents ................ $ 36,361,621 $ 27,762,378
Accounts receivable, trade, net .......... 3,585,824 3,703,625
Unbilled revenue ......................... 1,469,215 119,287
Inventories (note 3) ..................... 6,876,002 8,972,939
Prepaid expenses and other current assets. 333,742 376,307
----------- -----------
Total current assets ............... 48,626,404 40,934,536
----------- -----------
Property and equipment ...................... 14,346,200 24,694,211
Less: Accumulated depreciation and
amortization ................... (9,370,156) (10,311,663)
----------- -----------
Net property and equipment ......... 4,976,044 14,382,548
Patents and other assets, net ............... 125,056 102,476
----------- -----------
Total assets ....................... $ 53,727,504 $ 55,419,560
=========== ===========
LIABILITIES AND STOCKHOLDERS' EQUITY
- -------------------------------------
CURRENT LIABILITIES:
Capital lease obligation, current ........ $ 9,557 $ 11,283
Accounts payable ......................... 1,624,451 2,540,050
Accrued liabilities ...................... 2,148,755 1,587,826
Deferred revenue ......................... 1,534,369 3,439,384
----------- -----------
Total current liabilities .......... 5,317,132 7,578,543
Capital lease obligation, noncurrent .... 30,073 21,277
----------- -----------
Total liabilities .................. 5,347,205 7,599,820
----------- -----------
STOCKHOLDERS' EQUITY:
Undesignated preferred stock, $.01 par
value Authorized 2,000,000 shares; none
issued ................................ -- --
Common stock, $.008 par value
Authorized 50,000,000 shares; issued
8,172,800 shares and 8,316,191 shares
in 1999 and 2000, respectively......... 65,382 66,530
Additional paid-in capital .............. 63,543,777 64,174,595
Accumulated deficit ..................... (15,228,860) (16,421,385)
----------- -----------
Total stockholders' equity ......... 48,380,299 47,819,740
----------- -----------
Total liabilities and stockholders'
equity............................ $ 53,727,504 $ 55,419,560
============ ============
See accompanying notes to financial statements.
3
IBIS TECHNOLOGY CORPORATION
STATEMENTS OF OPERATIONS
(UNAUDITED)
THREE MONTHS ENDED NINE MONTHS ENDED
SEPTEMBER 30, SEPTEMBER 30,
---------------------- -----------------------
1999 2000 1999 2000
---------- ---------- ---------- ----------
SALES AND REVENUE:
Product sales .............. $1,321,730 $2,066,965 $3,970,195 $5,152,330
Contract and other revenue.. 155,401 47,520 555,487 381,700
Equipment revenue .......... 3,205,071 407,103 9,711,809 4,946,900
---------- --------- ---------- ----------
Total sales and revenue
(notes 2 and 4)......... 4,682,202 2,521,588 14,237,491 10,480,930
COST OF SALES AND REVENUE:
Cost of product sales ...... 1,122,360 1,604,800 3,509,006 3,688,641
Cost of contract and other
revenue ................. 138,981 57,870 361,935 278,310
Cost of equipment revenue 2,384,458 168,560 6,937,189 3,049,761
---------- --------- ---------- ----------
Total cost of sales and
revenue ............... 3,645,799 1,831,230 10,808,130 7,016,712
---------- --------- ---------- ----------
Gross profit ............ 1,036,403 690,358 3,429,361 3,464,218
---------- --------- ---------- ----------
OPERATING EXPENSES:
General and administrative . 408,941 427,639 1,367,481 1,501,841
Marketing and selling ...... 261,516 400,117 714,298 1,255,649
Research and development.... 386,178 1,129,771 1,163,865 3,352,624
---------- --------- --------- ----------
Total operating
expenses .............. 1,056,635 1,957,527 3,245,644 6,110,114
---------- --------- --------- ----------
Income (loss) from
operations ............ (20,232) (1,267,169) 183,717 (2,645,896)
---------- --------- --------- ----------
OTHER INCOME (EXPENSE):
Interest income ............ 318,078 470,028 617,118 1,467,432
Interest expense ........... (8,436) (901) (39,961) (9,196)
Other ...................... (2,760) -- 21,360 (3,609)
---------- --------- --------- ----------
Total other income ...... 306,882 469,127 598,517 1,454,627
---------- --------- --------- ----------
Income (loss) before
income taxes .......... 286,650 (798,042) 782,234 (1,191,269)
Income tax expense ........... -- -- 1,256 1,256
---------- --------- --------- ----------
Net income (loss) ....... $ 286,650 $ (798,042) $ 780,978 $(1,192,525)
========== ========== ========= ==========
Net income (loss) per
common share:
Basic ....................... $ 0.04 $ (0.10) $ 0.11 $ (0.14)
========== =========== ========= ===========
Diluted ..................... $ 0.03 $ (0.10) $ 0.10 $ (0.14)
========== =========== ========= ===========
Weighted average number of
common shares outstanding:
Basic ....................... 7,643,845 8,309,867 7,162,780 8,272,000
========== =========== ========= ===========
Diluted ..................... 8,224,887 8,309,867 7,624,525 8,272,000
========== =========== ========= ===========
See accompanying notes to financial statements.
4
IBIS TECHNOLOGY CORPORATION
STATEMENTS OF CASH FLOWS
(UNAUDITED)
NINE MONTHS ENDED
SEPTEMBER 30,
1999 2000
------------ ------------
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income (loss) ........................ $ 780,978 $ (1,192,525)
Adjustments to reconcile net income
(loss) to net cash provided by (used in)
operating activities:
Depreciation and amortization .......... 1,035,398 1,097,641
Loss on sale of equipment .............. 2,550 (3,609)
Changes in operating assets and liabilities:
Accounts receivable, trade ......... (6,109,139) (117,801)
Unbilled revenue ................... 90,081 1,349,928
Inventories ........................ (239,401) (2,096,937)
Prepaid expenses and other current
assets ........................... 112,107 (42,565)
Accounts payable ................... 647,236 915,599
Accrued liabilities and deferred
revenue .......................... 221,071 1,344,086
----------- -------------
Net cash provided by (used in)
operating activities ............. (3,459,119) 1,253,817
----------- -------------
CASH FLOWS FROM INVESTING ACTIVITIES:
Additions to property and equipment, net . (695,459) (10,489,206)
Other assets ............................. (35,655) 11,250
----------- -------------
Net cash used in investing activities (731,114) (10,477,956)
----------- -------------
CASH FLOWS FROM FINANCING ACTIVITIES:
Payments of capital lease obligations .... (409,438) (7,070)
Exercise of stock options ................ 790,696 631,966
Proceeds from sale of common stock, net
of inssuance costs ..................... 25,539,624 --
------------ -------------
Net cash provided by financing activitie 25,920,882 624,896
------------ -------------
Net increase (decrease) in cash and
cash equivalents ................ 21,730,649 (8,599,243)
Cash and cash equivalents, beginning of period 12,819,366 36,361,621
------------ ------------
Cash and cash equivalents, end of period ..... $ 34,550,015 $ 27,762,378
============ ============
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid during the period for interest .. $ 39,961 $ 9,196
============ ============
See accompanying notes to financial statements.
5
IBIS TECHNOLOGY CORPORATION
NOTES TO FINANCIAL STATEMENTS
(UNAUDITED)
(1) INTERIM FINANCIAL STATEMENTS
- --------------------------------
The accompanying financial statements are unaudited, except for the
Balance Sheet as of December 31, 1999, and have been prepared by the Company in
accordance with generally accepted accounting principles.
In the opinion of management, the interim financial statements include
all adjustments which consist only of normal and recurring adjustments necessary
for a fair presentation of the Company's financial position and results of
operations. Results of operations for the interim periods are not necessarily
indicative of the results to be expected for the full year. These financial
statements should be read in conjunction with the financial statements of the
Company as of and for the year ended December 31, 1999 which are included in the
Annual Report on Form 10-K.
(2) REVENUE RECOGNITION
- -----------------------
Product and spare part sales are recognized upon shipment. For
equipment sales, the Company previously used the percentage of completion method
for recognizing revenue because there was significant engineering effort and
milestone payments involved. The Company is now building its equipment to stock
and recognizes revenue upon shipment. Revenue derived from consulting and
support services is recognized upon performance. Contract revenue is recognized
on the percentage-of-completion method. Provisions for anticipated losses are
made in the period in which such losses become determinable. Unbilled revenue
represents revenue earned but not yet billable based on the terms of the
contract which include shipment of the product, achievement of milestones or
completion of the contract.
(3) INVENTORIES
- ---------------
Inventories consist of the following:
DECEMBER 31, SEPTEMBER 30,
1999 2000
----------- ----------
Raw materials ............. $ 129,786 $ 93,462
Work in process ........... 46,639 130,458
Finished goods ............ 28,685 94,950
---------- ----------
Subtotal wafer inventory $ 205,110 $ 318,870
Equipment inventory ....... 6,670,892 8,654,069
---------- ----------
Total inventories ...... $6,876,002 $8,972,939
========== ==========
6
IBIS TECHNOLOGY CORPORATION
NOTES TO FINANCIAL STATEMENTS
(UNAUDITED)
(4) EARNINGS PER SHARE RECONCILIATION
- -------------------------------------
Net income (loss) per share of common stock is computed based upon the
weighted average number of shares outstanding during each period and including
the dilutive effect, if any, of stock options and warrants. SFAS 128 requires
the presentation of basic and diluted earnings (loss) per share for all periods
presented. As Ibis was in a net loss position for the three months ended
September 30, 2000 and the nine months ended September 30, 2000, common stock
equivalents of 373,344 and 455,671 shares, respectively, were excluded from the
diluted loss per share calculation as they would be antidilutive. As a result,
diluted loss per share is the same as basic loss per share for the three months
ended September 30, 2000 and the nine months ended September 30, 2000.
The reconciliation of the numerators and denominators of the basic and
diluted net income (loss) per common share computations for the Company's
reported net income (loss) is as follows:
THREE MONTHS ENDED NINE MONTHS ENDED
SEPTEMBER 30, SEPTEMBER 30,
---------------------- ----------------------
1999 2000 1999 2000
---------- ---------- ---------- ----------
Net income (loss) ............. $ 286,650 $ (798,042) $ 780,978 $(1,192,525)
========== ========== ========== ===========
Weighted average common
shares outstanding-basic ... 7,643,845 8,309,867 7,162,780 8,272,000
---------- ---------- ---------- -----------
Net additional common shares
upon assumed exercise of
stock options and warrants 581,042 -- 461,745 --
---------- ---------- ---------- -----------
Weighted average common
shares outstanding-diluted.. 8,224,887 8,309,867 7,624,525 8,272,000
========== ========== ========== ===========
Net income (loss) per common
share:
Basic ................ $ 0.04 $ (0.10) $ 0.11 $ (0.14)
========== ========== ========== ===========
Diluted ......... $ 0.03 $ (0.10) $ 0.10 $ (0.14)
========== ========== ========== ===========
(5) INDUSTRY SEGMENTS
- ---------------------
The Company's reportable segments are SIMOX-SOI Wafer Products, SIMOX
Equipment and Contract and Other Revenue. For purposes of segment reporting,
equipment, equipment spares and field service revenue are combined and reported
as SIMOX Equipment. Government contracts, other services and license revenue are
combined and reported as Contract and Other Revenue.
7
IBIS TECHNOLOGY CORPORATION
NOTES TO FINANCIAL STATEMENTS
(UNAUDITED)
The table below provides information for the three and nine months
ended September 30, 1999 and 2000 pertaining to the Company's three industry
segments.
SIMOX CONTRACT
WAFER SIMOX AND OTHER
PRODUCTS EQUIPMENT REVENUE TOTAL
--------- --------- -------- ------
NET REVENUES
- ------------
Three Months Ended September 30, 1999 $1,321,730 $3,205,071 $155,401 $4,682,202
Three Months Ended September 30, 2000 2,066,965 407,103 47,520 2,521,588
Nine Months Ended September 30, 1999 3,970,195 9,711,809 555,487 14,237,491
Nine Months Ended September 30, 2000 5,152,330 4,946,900 381,700 10,480,930
OPERATING INCOME (LOSS)
- -----------------------
Three Months Ended September 30, 1999 149,091 223,197 16,420 388,708
Three Months Ended September 30, 2000 34,699 (863,878) (10,351) (839,530)
Nine Months Ended September 30, 1999 277,629 1,080,016 193,552 1,551,197
Nine Months Ended September 30, 2000 308,560 (1,556,006) 103,390 (1,144,056)
ASSETS
- ------
September 30, 2000 14,809,513 11,908,837 30,200 26,748,550
CAPITAL EXPENDITURES
- --------------------
Three Months Ended September 30, 1999 23,177 3,749 -- 26,926
Three Months Ended September 30, 2000 5,050,769 391,948 -- 5,442,717
Nine Months Ended September 30, 1999 512,749 11,325 -- 524,074
Nine Months Ended September 30, 2000 9,422,863 800,552 -- 10,223,415
DEPRECIATION AND AMORTIZATION
- -----------------------------
OF PROPERTY AND EQUIPMENT
- -------------------------
Three Months Ended September 30, 1999 293,722 1,105 1,602 296,429
Three Months Ended September 30, 2000 348,900 21,585 833 371,318
Nine Months Ended September 30, 1999 880,133 45,281 5,221 930,635
Nine Months Ended September 30, 2000 909,930 106,655 2,319 1,018,904
8
IBIS TECHNOLOGY CORPORATION
NOTES TO FINANCIAL STATEMENTS
(UNAUDITED)
The table below provides the reconciliation of reportable segment
operating income (loss) and assets to Ibis' totals.
NINE MONTHS ENDED SEPTEMBER 30,
------------------------------
SEGMENT RECONCILIATION 1999 2000
- ---------------------- ---- ----
Income (Loss) Before Income Taxes:
Total operating income (loss) for
reportable segments $ 1,551,197 $ (1,144,056)
Corporate general & administrative
expenses (1,367,480) (1,501,840)
Net other income 598,517 1,454,627
------------- -------------
Income (loss) before income taxes 782,234 (1,191,269)
============= ==============
Capital Expenditures:
Total capital expenditures for
reportable segments 524,074 10,223,415
Corporate capital expenditures 171,385 265,791
------------ ---------------
Total capital expenditures 695,459 10,489,206
============ =============
Depreciation and Amortization:
Total depreciation and amortization
for reportable segments 930,635 1,018,904
Corporate depreciation and amortization 104,763 78,737
----------- ---------------
Total depreciation and amortization 1,035,398 1,097,641
=========== =============
12/31/99 9/30/00
Assets: --------- ---------
Total assets for reportable segments 16,703,042 26,748,550
Cash & cash equivalents not allocated
to segments 36,361,621 27,762,378
Other unallocated assets 662,841 908,632
------------ ------------
Total assets 53,727,504 55,419,560
========== ==========
9
IBIS TECHNOLOGY CORPORATION
PART I - ITEM 2
MANAGEMENT'S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS
OVERVIEW
Ibis Technology Corporation ("Ibis") was formed in October 1987 and
commenced operations in January 1988. Ibis' initial activities consisted of
producing and selling SIMOX-SOI wafers and conducting research and development
activities. This research led to the development of a proprietary second
generation implanter, the Ibis 1000, which we began selling in 1996, and to
other proprietary process technology.
Initially, much of our revenue was derived from research and
development contracts and sales of wafers for military applications. Over the
years, there has been a shift in revenue to sales of SIMOX-SOI wafers for
commercial applications and sales of Ibis 1000 implanters. To date, most of our
customers that have purchased wafers for commercial applications have done so
solely for the purpose of characterizing and evaluating the wafers or for pilot
production. Thus, historical sales are not necessarily indicative of future
operations because such sales would not be considered of a recurring nature.
During 1999 and 2000, Ibis experienced quarterly fluctuations due to
the timing of implanter equipment sales and dependence on a limited number of
customers. In addition, we previously used the percentage of completion method
for recognizing revenue on implanter sales because there was significant
engineering effort and milestone payments involved. Ibis is now building the
implanters to stock and recognizes revenue upon shipment. Consequently each Ibis
1000 sale has a significant impact on revenue for the period in which it is
shipped. We may also experience fluctuations in revenue due to shifts in
customer demands during the various stages of the SIMOX-SOI adoption cycle and
also as a result of the variety of wafer sizes and product demand placed on the
finite number of Ibis 1000 systems producing wafers.
RESULTS OF OPERATIONS
THIRD QUARTER ENDED SEPTEMBER 30, 2000 COMPARED TO THIRD QUARTER ENDED SEPTEMBER
30, 1999
PRODUCT SALES. Wafer product sales increased $745,235 or 56%, to
$2,066,965 for the third quarter ended September 30, 2000 from $1,321,730 for
the third quarter ended September 30, 1999. The increase in product sales is
primarily attributable to increased wafer sales to customers in Europe.
CONTRACT AND OTHER REVENUE. Contract and other revenue includes revenue
derived from government contracts, license agreements, characterization and
other services. Contract and other revenue decreased for the third quarter ended
September 30, 2000 to $47,520 from $155,401 for the third quarter ended
September 30, 1999, a decrease of $107,881 or 69%. This decrease is primarily
attributable to a decrease in revenues derived from government contracts,
license revenues, and other services.
EQUIPMENT REVENUE. Equipment revenue represents revenue
recognized from the sale of ibis 1000 implanters, sales of spare parts and field
service revenue. Equipment revenue decreased to $407,103 for the third quarter
ended september 30, 2000 from $3,205,071 for the third quarter ended september
30, 1999. This decrease is primarily attributable to lack of ibis 1000 implanter
sales this quarter. Ibis previously used the percentage of completion method for
recognizing revenue on implanter sales, which resulted in ibis recognizing
revenue on a
10
IBIS TECHNOLOGY CORPORATION
PART I - ITEM 2
MANAGEMENT'S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS (CONTINUED)
portion of multiple implanters for the quarter ended September 30, 1999
compared to no revenue recognized on implanters for the quarter ended
September 30, 2000. Field Service revenue accounted for $326,300 of equipment
revenue for the third quarter ended September 30, 2000 as compared to $49,649
of equipment revenue for the third quarter ended September 30, 1999. Sales of
spare parts accounted for $80,803 of equipment revenue for the third quarter
ended September 30, 2000 as compared to $622,422 of equipment revenue for the
third quarter ended September 30, 1999.
TOTAL SALES AND REVENUE. Total sales and revenue for the third
quarter ended September 30, 2000 was $2,521,588, a decrease of $2,160,614, or
46%, from total revenue of $4,682,202 for the third quarter ended September
30, 1999. This decrease resulted primarily from lack of implanter sales this
quarter which was offset by increased product sales.
TOTAL COST OF SALES AND REVENUE. Cost of product sales for the third
quarter ended September 30, 2000 was $1,604,800, as compared to $1,122,360
for the third quarter ended September 30, 1999, an increase of $482,440 or
43%. Cost of contract and other revenue for the third quarter ended September
30, 2000 was $57,870, as compared to $138,981 for the third quarter ended
September 30, 1999, a decrease of $81,111, or 58%. Cost of equipment revenue
for the third quarter ended September 30, 2000 was $168,560 as compared to
$2,384,458 for the third quarter ended September 30, 1999, a decrease of
$2,215,898 or 93%. The gross margin for all sales was 27% for the third
quarter ended September 30, 2000 as compared to 22% for the third quarter
ended September 30, 1999. The increase in gross margin percentage is
attributable to improved margins on wafer product sales and services. The
fundamental fixed cost nature of product sales, which was absorbed by a
larger number of wafers sold during the third quarter of 2000 as compared to
the same quarter in the previous year, resulted in a positive impact on
margins. Cost of contract and other revenue consists of labor and materials
expended during the quarter. Contract margins can vary from year to year
based on the type of contracts that Ibis enters into. Additionally, different
fee arrangements and indirect cost absorption can contribute to margin
variability.
GENERAL AND ADMINISTRATIVE EXPENSES. General and administrative
expenses for the third quarter ended September 30, 2000 were $427,639 (or 17%
of total revenue) as compared to $408,941 (or 9% of total revenue) for the
third quarter ended September 30, 1999, an increase of $18,698, or 5%.
MARKETING AND SELLING EXPENSES. Marketing and selling expenses for
the third quarter ended September 30, 2000 were $400,117 (or 16% of total
revenue) as compared to $261,516 (or 6% of total revenue) for the third
quarter ended September 30, 1999, an increase of $138,601, or 53%. The
increase in marketing and selling expenses is primarily a result of an
increase in the number of customer support personnel, public relations, and
product samples.
RESEARCH AND DEVELOPMENT EXPENSES. Internally funded research and
development expenses increased by $743,593 or 193%, to $1,129,771 (or 45% of
total revenue) for the third quarter ended September 30, 2000, as compared to
$386,178 (or 8% of total revenue) for the third quarter ended September 30,
1999. The increase is primarily due to an increase in personnel and
consultants hired for the Ibis design and development effort on our next
generation oxygen implanter, the Ibis 2000, and increased material expenses
on Ibis' wafer development program.
11
IBIS TECHNOLOGY CORPORATION
PART I - ITEM 2
MANAGEMENT'S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS (CONTINUED)
LOSS FROM OPERATIONS. The loss from operations for the third quarter
ended September 30, 2000 was $1,267,169 as compared to $20,232 for the third
quarter ended September 30, 1999, an increase of $1,246,937, or 6,163%. The
increase in loss from operations is primarily the result of lack of implanter
equipment sales and the increase in operating expenses, which were partially
offset by increased product sales.
OTHER INCOME (EXPENSE). Total other income for the third quarter
ended September 30, 2000 was $469,127 as compared to $306,882 for the third
quarter ended September 30, 1999, an increase of $162,245, or 53%. The
increase in total other income is primarily attributable to increased
interest income earned primarily on the proceeds from the August 1999 public
stock offering and reduced interest expense on capitalized leases.
INCOME (LOSS) BEFORE INCOME TAXES. The loss before income taxes was
$798,042 for the third quarter ended September 30, 2000, as compared to
income of $286,650 for the third quarter ended September 30 , 1999. The
decrease of $1,084,692, or 378%, is primarily due to lack of implanter
equipment sales and the increase in operating expenses, which were partially
offset by increased product sales and interest income.
NINE MONTHS ENDED SEPTEMBER 30, 2000 COMPARED TO NINE MONTHS ENDED
SEPTEMBER 30, 1999
PRODUCT SALES. Wafer product sales increased $1,182,135, or 30%, to
$5,152,330 for the nine months ended September 30, 2000 from $3,970,195 for
the nine months ended September 30, 1999. The increase in product sales is
primarily attributable to increased wafer sales by Ibis in Europe.
CONTRACT AND OTHER REVENUE. Contract and other revenue decreased for
the nine months ended September 30, 2000 to $381,700 from $555,487 for the
nine months ended September 30, 1999, a decrease of $107,881 or 69%. This
decrease is attributable to a decrease in revenues derived from government
contracts, other services, and decreased license revenue.
EQUIPMENT REVENUE. Equipment revenue decreased to $4,946,900 for the
nine months ended September 30, 2000 from $9,711,809 for the nine months
ended September 30, 1999. This decrease is attributable to the decreases in
implanter equipment and spare parts sales which were partially offset by an
increase in field service revenue. Ibis previously used the percentage of
completion method for recognizing revenue on implanter sales, which resulted
in Ibis recognizing revenue on a portion of multiple implanters in the first
nine months of 1999 compared to revenue recognized on one full implanter in
the first nine months of 2000. Field service revenue accounted for $469,400
of equipment revenue for the nine months ended September 30, 2000 as compared
to $130,610 of equipment revenue for the nine months ended September 30,
1999. Sales of spare parts accounted for $547,500 of equipment revenue for
the nine months ended September 30, 2000 as compared to $746,200 of equipment
revenue for the nine months ended September 30, 1999.
12
IBIS TECHNOLOGY CORPORATION
PART I - ITEM 2
MANAGEMENT'S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS (CONTINUED)
TOTAL SALES AND REVENUE. Total sales and revenue for the nine months
ended September 30, 2000 was $10,480,930, a decrease of $3,756,561, or 26%,
from total revenue of $14,237,491 for the nine months ended September 30,
1999. This decrease resulted primarily from decreased implanter equipment
sales which was partially offset by increased product sales.
TOTAL COST OF SALES AND REVENUE. Cost of product sales for the nine
months ended September 30, 2000 was $3,688,641, as compared to $3,509,006 for
the nine months ended September 30, 1999, an increase of $179,635 or 5%. Cost
of contract and other revenue for the nine months ended September 30, 2000
was $278,310, as compared to $361,935 for the nine months ended September 30,
1999, a decrease of $83,625, or 23%. Cost of equipment revenue for the nine
months ended September 30, 2000 was $3,049,761 as compared to $6,937,189 for
the nine months ended September 30, 1999, a decrease of $3,887,428 or 56%.
The gross margin for all sales was 33% for the nine months ended September
30, 2000 as compared to 24% for the nine months ended September 30, 1999. The
increase in gross margin percentage is primarily attributable to improved
margins on products and equipment. The fundamental fixed cost nature of
product sales, which was absorbed by a larger number of wafers sold during
the first nine months of 2000 as compared to the same period in the previous
year, resulted in a positive impact on margins. The equipment margin
percentage increased primarily due to improved overhead absorption and
favorable material spending. Cost of contract and other revenue consists of
labor and materials expended during the period. Contract margins can vary
from year to year based on the type of contracts that Ibis enters into.
Additionally, different fee arrangements and indirect cost absorption can
contribute to margin variability.
GENERAL AND ADMINISTRATIVE EXPENSES. General and administrative
expenses for the nine months ended September 30, 2000 were $1,501,841 (or 14%
of total revenue) as compared to $1,367,481 (or 10% of total revenue) for the
nine months ended September 30, 1999, an increase of $134,360, or 10%. The
increase is due to increases in payroll and payroll related expenses and
professional services incurred in the nine months ended September 30, 2000.
MARKETING AND SELLING EXPENSES. Marketing and selling expenses for
the nine months ended September 30, 2000 were $1,255,649 (or 12% of total
revenue) as compared to $714,298 (or 5% of total revenue) for the nine months
ended September 30, 1999, an increase of $541,351, or 76%. The increase in
marketing and selling expenses is primarily a result of an increase in the
number of customer support personnel, and expenses related to public
relations and product samples.
RESEARCH AND DEVELOPMENT EXPENSES. Internally funded research and
development expenses increased by $2,188,759 or 188%, to $3,352,624 (or 32%
of total revenue) for the nine months ended September 30, 2000, as compared
to $1,163,865 (or 8% of total revenue) for the nine months ended September
30, 1999. The increase is primarily due to an increase in personnel and
consultants hired for Ibis' design and development effort on our next
generation oxygen implanter, the Ibis 2000, and increased material expenses
on Ibis' wafer development program.
13
IBIS TECHNOLOGY CORPORATION
PART I - ITEM 2
MANAGEMENT'S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS (CONTINUED)
INCOME (LOSS) FROM OPERATIONS. The loss from operations for the nine
months ended September 30, 2000 was $2,645,896 as compared to income of
$183,717 for the nine months ended September 30, 1999. The operating loss is
due primarily to decreased implanter equipment sales and increased operating
expenses, which were partially offset by increased product sales.
OTHER INCOME. Total other income for the nine months ended September
30, 2000 was $1,454,627 as compared to $598,517 for the nine months ended
September 30, 1999, an increase of $856,110, or 143%. The increase in total
other income is primarily attributable to increased interest income earned
primarily on the proceeds from the August 1999 public stock offering and
reduced interest expense on capitalized leases.
INCOME (LOSS) BEFORE INCOME TAXES. The loss before income taxes was
$1,191,269 for the nine months ended September 30, 2000, as compared to
income of $782,234 for the nine months ended September 30, 1999. The decrease
of $1,973,503, or 252%, is due primarily to decreased implanter equipment
sales and increased operating expenses, which were partially offset by
increased product sales and interest income.
LIQUIDITY AND CAPITAL RESOURCES
As of September 30, 2000, Ibis had cash and cash equivalents of
$27,762,378, reflecting in large part our receipt of approximately $25
million in net proceeds from the August 1999 sale of 1,000,000 shares of
Common Stock. During the nine months ended September 30, 2000, the Company
generated $1,253,817 in cash from operating activities as compared to cash
used by operations in the amount of $3,459,119 for the same period in 1999.
Depreciation and amortization expense for the nine months ended September 30,
2000 and 1999 was $1,097,641 and $1,035,398, respectively. This accounted for
10% and 7% of total revenue, respectively. Due to the capital intensive
nature of Ibis' business and the anticipated expansion of its facilities and
production capacity, management expects that depreciation and amortization
will continue to be a significant portion of its expenses. To date, Ibis'
working capital requirements have been funded primarily through debt and
equity financings. The principal use of cash during the nine months ended
September 30, 2000 was to fund additions to property and equipment which
totaled $10,489,206. As of September 30, 2000, the Company had invested
$26,634,241 in property and equipment. At September 30, 2000, Ibis had
commitments to purchase approximately $4,789,728 in material or subassemblies
to be used for manufacturing Ibis 1000 implanters and $809,655 in capital
equipment purchases.
We anticipate that we may be required to raise substantial
additional capital in the future in order to finance further expansion of our
manufacturing capacity and our research and development programs. Our
existing cash resources together with funds generated from operations are
believed to be sufficient to support Ibis' operations on our anticipated
scale for at least the next 18 months. Management of Ibis currently believes
that this anticipated scale of operations will include the addition of Ibis
1000 oxygen implanters (in addition to our oxygen implanters currently
on-line), the purchase of support equipment, the expansion of Ibis'
facilities, and the design and development of the next generation oxygen
implanter, the Ibis 2000. Additional implanters are expected to be
transferred to production at various times as additional capacity is needed
to meet demand.
14
IBIS TECHNOLOGY CORPORATION
PART I - ITEM 2
MANAGEMENT'S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS (CONTINUED)
NEW ACCOUNTING PRONOUNCEMENTS
In June 1998, the Financial Accounting Standards Board issued SFAS
133, "Accounting for Derivative Instruments and Hedging Activities" ("SFAS
133") that establishes accounting and reporting requirements for derivative
instruments and for hedging activities. SFAS 133 requires companies to
recognize all derivatives as either assets or liabilities in the statement of
financial position at fair value. If certain conditions are met, a derivative
may be specifically designated as a hedge of the exposures to changes in fair
value of recognized assets or liabilities or unrecognized firm commitments, a
hedge of the exposure to variable cash flows of a forecasted transaction, or
a hedge of the foreign currency exposure of a net investment in a foreign
operation, unrecognized firm commitments, an available-for-sale security or a
foreign-currency denominated forecasted transaction. The accounting for
changes in fair value under SFAS 133 depends on the intended use of the
derivative and the resulting designation. In June 1999, the FASB decided that
the effective date for adopting the requirements of SFAS 133 should be
delayed to fiscal years beginning after June 15, 2000. This delay, published
as SFAS 137, applies to quarterly and annual financial statements. In June
2000, the FASB issued SFAS 138, which addresses a limited number of issues
causing implementation difficulties for numerous entities that apply SFAS
133. Ibis is currently evaluating the effect SFAS 133 will have on the
results of its operations and its financial position.
In December 1999, the Securities and Exchange Commission issued
Staff Accounting Bulletin No. 101 ("SAB No. 101"), "Revenue Recognition in
Financial Statements". This bulletin, as amended, established guidelines for
revenue recognition and was originally effective for periods beginning after
March 15, 2000. In June 2000, the SEC announced that the effective date of
SAB 101 was being delayed until no later than the quarter ending December 31,
2000. The Company does not expect this to have a material impact on its
financial condition or results of operations as the Company has complied with
SAB 101.
In March 2000, the FASB issued Interpretation No. 44, "Accounting
for Certain Transactions Involving Stock Compensation", an interpretation of
APB Opinion No. 25, "Accounting for Stock Issued to Employees". This
interpretation clarified the application of Opinion 25, among other issues:
(a) the definition of an employee for purposes of applying Opinion 25, (b)
the criteria for determining whether a stock ownership plan qualifies as
noncompensatory, (c) the accounting implications of various modifications to
the terms of a previously fixed stock option or award, and (d) the accounting
for the exchange of stock compensation awards in a business combination. The
Interpretation is effective July 1, 2000 and the effects of applying the
Interpretation are recognized on a prospective basis. The adoption of this
Interpretation did not have a material impact on its financial condition or
results of operations.
EFFECTS OF INFLATION
The Company believes that over the past three years inflation has
not had a significant impact on the Company's sales or operating results.
BUSINESS OUTLOOK
This Form 10-Q contains forward-looking statements within the
meaning of the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995 including statements regarding the continuation of
fluctuations in revenue, the expectation that depreciation and amortization
will continue to be a significant portion
15
IBIS TECHNOLOGY CORPORATION
PART I - ITEM 2
MANAGEMENT'S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS (CONTINUED)
of expenses, the need for future additional capital and the sufficiency of
our current capital, and the anticipated scale of Ibis' operations. Such
statements are based on our current expectations and are subject to a number
of factors and uncertainties which could cause actual results to differ
materially from those described in the forward-looking statements. Such
factors and uncertainties include, but are not limited to, the uncertainty
that the performance advantages of SIMOX-SOI wafers will continue to be
realized commercially or that a commercial market for SIMOX-SOI wafers will
continue to develop; the dependence by Ibis on key customers (during 1997,
1998 and 1999, revenues from two customers averaged in the aggregate between
39% and 81% of our revenues, so that the loss of one or more of these major
customers and the failure of Ibis to obtain other sources of revenue could
have a material adverse impact on us); the loss of the services of one or
more of our key individuals, which could have a material adverse impact on
Ibis; the dependence by Ibis on key suppliers, so that the loss of services
of one or more suppliers could have a material adverse impact on us; the
development of competing or superior technologies and products from
manufacturers, many of which have substantially greater financial, technical
and other resources than us; Ibis' lack of experience in producing commercial
quantities of our products at acceptable costs; our ability to successfully
complete the manufacture of our implanters and that these implanters will be
accepted by our customers; Ibis' ability to develop and maintain strategic
alliances for the manufacturing, marketing and distribution of our products
and sale of equipment; the cyclical nature of the semiconductor industry,
which has negatively affected our sales of SIMOX-SOI wafers during industry
downturns and which could continue to do so in the future; the limited
availability of critical materials and components for wafer products and
implanters, as a shortage of such materials and components or a significant
increase in the price thereof could have a material adverse effect on our
business and results of operations; the availability of additional capital to
fund expansion on acceptable terms, if at all; and general economic
conditions.
PART I - ITEM 3
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
The exposure of market risk associated with risk-sensitive
instruments is not material to the Company, as the Company does not transact
its sales denominated in other than United States dollars, invests primarily
in short-term commercial paper, holds its investments until maturity and has
not entered into hedging transactions.
16
IBIS TECHNOLOGY CORPORATION
PART II
OTHER INFORMATION
Item 1 - LEGAL PROCEEDINGS
None
Item 2 - CHANGES IN SECURITIES
None
Item 3 - DEFAULTS UPON SENIOR SECURITIES
None
Item 4 - SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
None
Item 5 - OTHER INFORMATION
None
Item 6 - EXHIBITS AND REPORTS ON FORM 8-K
(a) Exhibits furnished as Exhibits hereto:
3.1 Restated Articles of Organization
3.1.1 Articles of Amendment to the Restated Articles of
Organization
3.1.2 Articles of Amendment to the Restated Articles of
Organization
27 Financial Data Schedule
(b) Reports on Form 8-K:
The Company filed with the Securities and Exchange Commission
on July 27, 2000 a Current Report on Form 8-K for the July 25,
2000 event announcing the final results for the second quarter
ended June 30, 2000.
17
IBIS TECHNOLOGY CORPORATION
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
Ibis Technology Corporation
Date: November 6, 2000 By: /s/Debra L. Nelson
--------------------------------
Debra L. Nelson
Chief Financial Officer,
Treasurer and Clerk
(principal financial and
accounting officer)
Date: November 6, 2000 By: /s/Thomas F. Lacey
--------------------------------
Thomas F. Lacey
Controller and Assistant Treasurer
18
IBIS TECHNOLOGY CORPORATION
EXHIBIT INDEX
EXHIBIT NO. DESCRIPTION PAGE
- ----------- ----------- ----
3.1 Restated Articles of Organization 20
3.1.1 Articles of Amendment to the Restated Articles of Organization 31
3.1.2 Articles of Amendment to the Restated Articles of Organization 35
27 Financial Data Schedule 39
19